Not Yet RecruitingPhase 3ACTRN12605000681651
Long Term Immunogenicity of the JE Vaccine IC51
Long Term Immunogenicity of the Japanese Encephalitis Vaccine IC51 (JE-PIV).
Sponsor
Intercell AG
Enrollment
600 participants
Start Date
Oct 12, 2006
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Healthy subjects. Written informed consent obtained prior to study entry.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A Phase III follow-up study to assess long term safety 6 months after the first vacccination with IC51 and to assess in a subgroup the long term immunogenicity up to 24 months
A Phase III follow-up study to assess long term safety 6 months after the first vacccination with IC51 and to assess in a subgroup the long term immunogenicity up to 24 months
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000681651